Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Bone Therapeutics S.A. (Euronext Brussels + Paris: BOTHE)

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation. Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal Phase III program has been approved by the relevant authorities allowing the start of the study. Bone Therapeutics’ other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications. Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com. *

 

Period Start 2006-01-01 established
  Group Bone Therapeutics (Group)
Products Industry ALLOB® allogeneic bone cell product
  Industry 2 JTA-004 off-the-shelf protein solution (Bone Therapeutics)
Persons Person Forte, Miguel (Bone Therapeutics 202001– CEO before Zelluna + Bone Therapeutics + TxCell + UCB + Nabi + BMS + EMA)
  Person 2 Vandebroek, Jean-Luc (Bone Therapeutics 202004 CFO)
     
Region Region Gosselies
  Country Belgium
  Street 7 Rue Auguste Piccard
  City 6041 Gosselies
  Tel +32-2-529-5990
    Address record changed: 2020-05-06
     
Basic data Employees C: 51 to 100 (2018-12-31)
  Currency EUR
  Annual sales 5,079,000 (income, operating, total, consolidated (2018) 2018-12-31)
  Profit -14,142,000 (2018-12-31)
  Cash 8,174,000 (2018-12-31)
     
    * Document for �About Section�: Bone Therapeutics S.A.. (4/29/20). "Press Release: Bone Therapeutics Secures EUR 11.0 Million Financing". Gosselies.
     
   
Record changed: 2020-05-06

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for Bone Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top